Business
BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results
- Full-year 2019 Total Revenues Increased 14% to $1.7 billion - 17% Increase in Net Product Revenues from Products Marketed by BioMarin to $1.6 billion in
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"- Full-year 2019 Total Revenues Increased 14% to $1.7 billion\n - 17% Increase in Net Product Revenues from Products Marketed by BioMarin to $1.6 billion in Full-year 2019\n - 2020 Full-year Total Revenue Growth Expected to be Between 14% and 20%\n - For the Full-year 2020 BioMarin Expects for the First Time to be Profitable on a GAAP Basis\n - U.S. and European Marketing Submissions for Valoctocogene Roxaparvovec for Severe Hemophilia A Accepted by FDA and EMA under Priority Review and Accelerated Assessment, Respectively; Approval Decisions Expected in Second Half of 2020\n - Phase 3 Study with Vosoritide for Achondroplasia Demonstrated Highly Statistically Significant Increase (p","length":740,"tagName":"div"}]